Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries
Open accessThe DOI matches its Crossref record.
Abstract
Aims Many drugs belonging to different therapeutic classes appear to share a potentially fatal side‐effect: ventricular tachyarrhythmias associated with QT prolongation. The aim of this study was to assess the relevance and the magnitude of the problem in seven countries by grouping all nonantiarrhythmic drugs according to the type of evidence on QT prolongation and analysing their sales data. Methods We divided all nonantiarrhythmic QT‐prolonging agents into the following categories (in increasing order of clinical relevance): group A, drugs with published clinical or preclinical evidence on QT prolongation or with relevant official warnings; group B, drugs with published clinical or preclinical evidence; group C, drugs with published clinical evidence; group D, drug with published clinical evidence on torsades de pointes or ventricular arrhythmias associated with QT prolongation; group E, drugs belonging to group D with official warnings. We retrieved 1998 sales data from community pharmacies in seven countries (Australia, Denmark, England, Germany, Greece, Italy and Sweden). Data for individual agents were expressed as defined daily doses per 1000 inhabitants per day (DDD/1000/day). Overall use in each country was calculated for each drug group. Groups D and E were considered as the most clinically relevant. Results Among the 102 nonantiarrhythmic agents meeting at least one of the inclusion criteria, 33 drugs had sales data ≥1 DDD/1000/day and 71 drugs had a use ≥0.1 DDD/1000/day in at least one country. Among the 37 nonantiarrhythmic agents with published reports of ventricular arrhythmias associated with QT prolongation, 12 compounds had sales data ≥1 DDD/1000/day. Total consumption in each country ranged: from 51.9 to 94.7 DDD/1000/day for group A; from 51.6 to 92.7 DDD/1000/day for group B; from 37.1 to 76.6 DDD/1000/day for group C; from 12.9 to 29.1 DDD/1000/day for group D; and from 5.8 to 15.3 DDD/1000/day for group E. Conclusions In spite of wide variations in the sales of individual agents, the overall extent of use of nonantiarrhythmic QT‐prolonging drugs was of the same order of magnitude in all countries. The significant use of drugs belonging to categories D and E should prompt careful risk/benefit assessment of each agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Myerburg, R. J., Quinones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,973
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
Writing Committee Members, Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., et al. (2006) · Europace · doi:10.1093/europace/eul108 · Cited by 738
Robinson, R. T. C. E., Harris, N. D., Ireland, R. H., Macdonald, I. A., & Heller, S. R. (2004) · Diabetologia · doi:10.1007/s00125-003-1292-4 · Cited by 137
Metadata
- Authors
- De Ponti, F., Poluzzi, E., Vaccheri, A., Bergman, U., Bjerrum, L., Ferguson, J., Frenz, K. J., McManus, P., Schubert, I., Selke, G., Terzis‐Vaslamatzis, G., & Montanaro, N.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2002-08
- Volume
- 54
- Issue
- 2
- Pages
- 171-177
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1835558948
- Cited by
- 43
- References
- 0
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries. https://app.cochat.ai/papers/10.1046/j.1365-2125.2002.01617.x
- The paper
- De Ponti, F., Poluzzi, E., Vaccheri, A., Bergman, U., Bjerrum, L., Ferguson, J., Frenz, K. J., McManus, P., Schubert, I., Selke, G., Terzis‐Vaslamatzis, G., & Montanaro, N. (2002). Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2002.01617.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.